COMPASS Pathways plc (NASDAQ:CMPS) Short Interest Up 6.7% in April

COMPASS Pathways plc (NASDAQ:CMPS) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 3,340,000 shares, a growth of 6.7% from the March 31st total of 3,130,000 shares. Based on an average daily trading volume, of 705,600 shares, the short-interest ratio is currently 4.7 days.

COMPASS Pathways Stock Down 1.1 %

Shares of COMPASS Pathways stock opened at $8.48 on Thursday. COMPASS Pathways has a 1-year low of $5.01 and a 1-year high of $12.75. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.33 and a current ratio of 13.33. The stock’s 50 day simple moving average is $9.57 and its 200-day simple moving average is $8.46.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). On average, equities analysts anticipate that COMPASS Pathways will post -2.4 earnings per share for the current year.

Insider Buying and Selling at COMPASS Pathways

In other news, major shareholder Ekaterina Malievskaia sold 25,750 shares of the stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $8.65, for a total transaction of $222,737.50. Following the sale, the insider now directly owns 4,036,154 shares of the company’s stock, valued at approximately $34,912,732.10. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, major shareholder Ekaterina Malievskaia sold 25,750 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $8.65, for a total transaction of $222,737.50. Following the completion of the transaction, the insider now directly owns 4,036,154 shares of the company’s stock, valued at approximately $34,912,732.10. The sale was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder George Jay Goldsmith sold 23,881 shares of COMPASS Pathways stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $8.53, for a total transaction of $203,704.93. Following the completion of the sale, the insider now directly owns 3,986,523 shares in the company, valued at approximately $34,005,041.19. The disclosure for this sale can be found here. Over the last quarter, insiders sold 140,601 shares of company stock valued at $1,338,911. Corporate insiders own 4.25% of the company’s stock.

Institutional Investors Weigh In On COMPASS Pathways

Several hedge funds and other institutional investors have recently bought and sold shares of the company. PFM Health Sciences LP boosted its holdings in COMPASS Pathways by 540.7% in the 4th quarter. PFM Health Sciences LP now owns 338,761 shares of the company’s stock valued at $2,964,000 after purchasing an additional 285,890 shares during the last quarter. Affinity Asset Advisors LLC purchased a new stake in shares of COMPASS Pathways during the 4th quarter valued at approximately $4,812,000. Quest Partners LLC acquired a new position in COMPASS Pathways in the fourth quarter valued at approximately $33,000. Jump Financial LLC purchased a new position in COMPASS Pathways in the fourth quarter worth approximately $371,000. Finally, EWA LLC purchased a new position in COMPASS Pathways in the fourth quarter worth approximately $107,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on CMPS shares. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research report on Tuesday. Morgan Stanley started coverage on COMPASS Pathways in a research report on Monday, April 1st. They set an “overweight” rating and a $30.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $120.00 price objective on shares of COMPASS Pathways in a report on Friday, March 1st. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, COMPASS Pathways presently has an average rating of “Buy” and a consensus target price of $47.40.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.